MentalHealthDaily

Psilocybin for Depression: Optimal Dosages for Antidepressant Effects (2023 Review)

by GLOOM

Recent research has provided compelling evidence on the therapeutic potential of psilocybin, a naturally occurring psychedelic, in treating depression. A systematic review and dose-response meta-analysis shed light on the optimal dosage of psilocybin for depression, revealing variations in effectiveness based on patient subgroups and associated risks. Highlights: Psilocybin showed significant antidepressant effects, with optimal dosages …

Caffeine & Depression: Lower Risk with >90 mg per Day in Adults (2022 Study)

by GLOOM

In the quest to understand the intricate links between our dietary habits and mental health, a recent study leveraging data from the National Health and Nutrition Examination Survey (NHANES) 2017-2018 offers new insights into how caffeine consumption correlates with depression. This comprehensive analysis reveals that moderate caffeine intake might have a protective effect against depression, …

Zuranolone for Depression: Rapid Efficacy & Safety in Clinical Trials (2023 Review)

by GLOOM

Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …

Niacin & Depression: Moderate Vitamin B3 Intake May Be Optimal for Mood

by GLOOM

New research suggests a U-shaped relationship between dietary niacin and depression risk, with the lowest risk around 36 mg/day. Key Facts: Moderate niacin intake was associated with a 24-32% lower odds of depression compared to the lowest intake. The relationship was U-shaped – higher and lower intakes were associated with higher depression risk. 36 mg/day …

Pantoprazole (Protonix) vs. Omeprazole (Prilosec)

by GLOOM

Pantoprazole and Omeprazole are medications classified as proton-pump inhibitors (PPIs) and are commonly prescribed for the management of medical conditions in which stomach acid reduction is of therapeutic benefit. Chemists at Byk Gulden, a subsidiary of Altana (a German chemical company), are credited with the synthesis of pantoprazole in 1985 – whereas Swedish chemists at …

Lexapro (Escitalopram) vs. Prozac (Fluoxetine)

by GLOOM

Lexapro (escitalopram) and Prozac (fluoxetine) are two medications within the selective-serotonin reuptake inhibitors (SSRI) classification that are commonly administered for the treatment of neuropsychiatric disorders. The development of Lexapro (escitalopram) was initiated in 1997 by Lundbeck and Forest Laboratories – whereas the development of Prozac (fluoxetine) was initiated in the 1970s by chemists (Bryan Molloy …

Pregabalin (Lyrica) vs. Gabapentin (Neurontin)

by GLOOM

Lyrica (pregabalin) and Neurontin (gabapentin) are both classified as “gabapentinoids” (i.e. α2δ ligands). As gabapentinoids, Lyrica (pregabalin) and Neurontin (gabapentin) are chemical analogues of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) that interact with α2δ subunit-containing voltage-dependent calcium channels. Development of gabapentin (Neurontin) was initiated in the 1970s by chemists at the pharmaceutical company Parke-Davis – …